Researchers Develop Idiopathic Pulmonary Fibrosis Prediction Models For Mortality in SSc-ILD Patients

ProMetic’s Experimental IPF Therapy PBI-4050 Demonstrates Anti-Fibrotic Properties in Human Cells

ProMetic Life Sciences Inc. recently validated the potential for its experimental drug target PBI-4050 to treat patients with idiopathic pulmonary fibrosis. Two presentations at the 2015 European Renal Association Annual Meeting identified that PBI-4050 reduces fibrosis in human cells. “Our data correlates the regulation activity of PBI-4050 on key fibrotic…

Aeolus Pharmaceuticals Reports on Experimental IPF Therapy AEOL 10150

John McManus, Chief Executive Officer, presented an outline of Aeolus’ development programs with a focus on the company’s progress regarding its contract with the Biomedical Advanced Research and Development Authority (“BARDA”), during the LD Micro Invitational meeting that took place last December in Los Angeles. The details of that meeting were recently…

Experimental Therapy May Promote Survival and Decrease Lung Fibrosis in Pulmonary Fibrosis Patients

RestorGenex Pharmaceuticals, a biotechnology company developing innovative therapeutics for a large spectrum of diseases, including cancer and those of the dermatology and ophthalmology spectrum, recently presented at the American Thoracic Society International Conference in Denver, Colorado their latest results using RES-529 as a potential treatment for idiopathic pulmonary fibrosis.

Veracyte Presents Results of Molecular Classifier for the Diagnosis of Non-Surgical IPF

Veracyte, Inc. a biotechnology company working in the field of molecular cytology, recently presented new results showing that its molecular classifier can distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILDs) in bronchoscopy-derived samples. The results indicate that the molecular classifier is able to help patients avoid invasive,…

Boehringer Ingelheim Presents Positive Data on Idiopathic Pulmonary Fibrosis Therapy OFEV at ATS Conference

Boehringer Ingelheim recently announced positive results regarding the safety, tolerability and efficacy of FDA-approved OFEV® (nintedanib*) in patients with idiopathic pulmonary fibrosis (IPF). The results were recently presented during the 2015 International Conference of the American Thoracic Society (ATS), which took place in Denver, and reveal continued long-term effectiveness in…

Pulmonary Fibrosis Foundation Honors Passing of Ambassador Diane Reichert

The Pulmonary Fibrosis Foundation (PFF) recently expressed its sadness over the loss of PFF Ambassador Diane Reichert, who has passed away. Diane received a diagnosis of idiopathic pulmonary fibrosis (IPF) in 2013, after which she became an Ambassador for the Foundation to help assist and raise awareness about her own disease. According to…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums